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ABSTRACT
Background Both the incidence of myocardial infarction
(MI) and short-term case fatality have declined in the
UK. However, little is known about trends in longer-term
survival following an MI. The aim of the study was to
investigate trends in longer-term survival, alongside
trends in medication prescribing in primary care.
Methods Data came from 218 general practices
contributing to the Health Improvement Network, a
UK-wide primary care database. 3-year survival and
medication use were determined for 6586 men and 3766
women who had an MI between 1991 and 2002 and had
already survived 3 months.
Results Adjusting for age and gender, the 3-year post-
MI case-fatality rate among 3-month survivors fell by
28% (95% CI 13 to 40), from 83 deaths per 1000 person-
years for MI occurring in 1991e2 to 61 deaths per 1000
person-years for MI in 2001e2. Relative declines in the
case-fatality rate of 37% (20 to 50) and 14% ( 11 to 34)
were observed for men and women, respectively
(p¼0.06 for interaction). Prescribing in the 3 months
following the MI of lipid-regulating drugs increased from
3% of patients in 1991 to 79% in 2002, prescribing of
beta-blockers increased from 26% to 68%, prescribing of
ACE inhibitors increased from 11% to 71% and
prescribing of anti-platelet medication increased from
46% to 86%.
Conclusion There has been a moderate improvement in
longer-term survival following an MI, distinct from
improvements in short-term survival, although men may
have beneﬁted more than women. Increased medication
prescribing in primary care may be a contributing factor.
There has been a considerable decline in mortality
from coronary heart disease (CHD) in recent
decades in the UK.
1 This is in line with CHD
mortality declines in western Europe and the USA,
1
although in other major regions CHD mortality is
increasing.
23Despite the decline, CHD remains the
leading cause of death in the UK. The decline in
CHD mortality may be attributable to a decline in
CHD incidence, or to improved survival of patients
with CHD, or a combination of the two. Previous
studies suggest that there has been a considerable
decline in the incidence of myocardial infarction
(MI), the dominant manifestation of CHD, which
may be responsible for a large portion of the
associated decline in mortality.
4e7 Concurrent
contributing declines in the UK in short-term case
fatality (up to 28 days or before discharge from
hospital) have also been reported.
148However,
trends in longer-term survival following an MI in
the UK are less well documented. Although one
earlier report has suggested that longer-term
survival had improved in the UK (speciﬁcally in
Scotland),
8 this report included events only up to
1995. There is a lack of data on more recent trends.
Moreover, analyses of temporal trends in longer-
term survival in other populations often include
survival in the short-term in the longer-term
survival estimates. It is not clear, therefore,
whether the reported decline in long-term fatality
reﬂects almost solely the declines in immediate case
fatality, or whether there are additional distinct
longer-term declines. Patients with a history of MI,
having survived the previous MI, accounted for
almost 40% of out-of-hospital CHD deaths
between 1983 and 1997 in the FINAMI study,
9
emphasising the importance of longer-term survival
from MI beyond the immediate period after the MI,
on reducing overall population CHD mortality.
The objective of this study, therefore, was to
investigate recent UK-wide time trends, between
1991 and 2005, in longer-term survival following an
MI, among men and women who had already
survived a 3-month period after the MI. Concurrent
trends prescribing of evidenced-based medication in
primary care up to 3 months following the MI
event were also explored.
METHODS
THIN data
The Health Improvement Network (THIN)
10
database is a UK-wide general practice database
comprising computerised anonymised longitudinal
patient records retrieved from more than 300
participating general practitioners (GPs) across the
UK. Demographic information as well as all
medical diagnoses and prescriptions made at every
GP visit are recorded. Data are continuously
collected and updated. Each patient is assigned
a follow-up start date, as the latest of two possible
dates: (1) the date that the patient registered at
a contributing GP and (2) the date by which both
the practice was fully using their computer system
for recording of diagnoses and prescriptions (an
average of at least one medical diagnosis, two
prescriptions and one additional health data, eg,
a blood pressure measurement, recorded per patient
per year), and computerised recording of patient
< An additional table is
published online only. To view
these ﬁles please visit the
journal online (http://jech.bmj.
com).
1Department of Primary Care
and Population Health,
University College London,
London, UK
2Division of Community Health
Sciences, St George’s,
University of London, London,
UK
3Division of Public Health,
University of Liverpool,
Liverpool, UK
Correspondence to
Sarah Hardoon, Department of
Primary Care and Population
Health, Division of Population
Health, UCL Medical School,
Royal Free Campus, Rowland
Hill Street, London NW3 2PF,
UK; s.hardoon@ucl.ac.uk
Accepted 26 February 2010
Published Online First
1 June 2010
This paper is freely available
online under the BMJ Journals
unlocked scheme, see http://
jech.bmj.com/site/about/
unlocked.xhtml
770 J Epidemiol Community Health 2011;65:770e774. doi:10.1136/jech.2009.098087
Research reportdeath (the principal outcome) for the practice had reached an
acceptable level. Recording of deaths in the practice was deemed
to have reached an acceptable level when the observed number
of deaths in the practice ﬁrst matched the expected number of
deaths for that time period, given the ageegender distribution of
the practice (using the ‘acceptable mortality rate date’ as deﬁned
by the database providers).
11 As a further data quality control,
only practices with at least 5 years worth of data were included
in the analyses (218 practices). The data used for this study
cover a 15-year period from 1 January 1991 to 31 December
2005.
Study sample
The study sample consisted of all patients in the participating
practices who had had a diagnosis of MI between 1991 and 2002
inclusive, and who were aged 35 years or over at the time of the
MI. Only patients with an MI before 31 December 2002 were
included to ensure an equal 3 years potential follow-up for all
subjects. A patient was identiﬁed as having had an MI if the GP
had recorded a diagnosis of MI in the patient’s records. Medical
diagnoses in THIN GPs are recorded using Read codes, which are
a clinical classiﬁcation system of diagnoses, symptoms and
history widely used in UK computerised GP records.
12 We
identiﬁed all Read codes that referred to acute MI or to an ECG
result corresponding to an MI, based on previously published
code lists.
13 The earliest record of an MI diagnosis was retained
for each patient and the patient was only included if this MI
occurred at least 12 months after the patient start date. This
ensured that the dataset was consistent across all calendar years
in being limited to those patients who had not had another MI
in the previous year.
Principal outcome
The principal outcome was death within 3 years of the MI,
given that the patient had survived to 3 months. A patient was
identiﬁed as having died if their registration status was ‘death’ or
they had a medical diagnosis with a Read code that referred to
death of the patient or they had an additional health data code
referring to death. The date of death was given with the death
record. The survival period was chosen a priori. Three months
was chosen as a start date as the outcome of interest was longer-
term survival, once a patient has survived the immediate higher-
risk interval after the MI, ensuring as far as possible that the
patient has been discharged from the initial hospitalisation.
Three months also allowed enough time for medication use to
be assessed before the start date of the follow-up for the
outcome (see below), leading to a fairer comparison between the
medication and survival trends.
Assessment of medication use
The use of relevant medications post-MI in primary care was
established from records of prescriptions. Medication types were
classiﬁed using British National Formulary (BNF) codes.
14 The
following categories of medications, based on current UK
Department of Health guidelines,
15 were considered: lipid-
lowering drugs including, but not exclusively, statins (BNF
chapter 2.12), beta-blockers (BNF chapter 2.4), ACE inhibitors,
including angiotensin receptor blockers (BNF chapters 2.5.5.1
and 2.5.5.2) and anti-platelet drugs including aspirin and clopi-
dogrel (BNF chapter 2.9). At least one record of a prescription
from a relevant BNF medication category within 3 months of
the date of the patient’s MI was taken to indicate that the
patient was receiving that category of medication. A 3-month
period was used to allow as far as possible time for the patient to
have left hospital and used up any prescriptions given in
hospital, so that at least one prescription would be required in
primary care. A lack of prescription would thus represent the
patient not taking the medication, rather than the patient still
using medications prescribed in hospital.
Statistical analyses
The case-fatality rate between 3 months and 3 years after an MI
was calculated for every two calendar years from 1991 to 2002
(the year that the MI occurred), standardised by the ageegender
distribution of the study population in 2001e2. The average age-
adjusted annual change in the case-fatality rate was estimated
from Poisson regression of an indicator for death on the calendar
year of MI, including age at the time of MI (as a continuous
variable) and gender as covariates. Squared terms for age were
not signiﬁcant so were excluded from the ﬁnal models. Gener-
alised estimating equations with robust standard errors were
used in the regression to adjust for variation between different
GPs. Follow-up times of patients were censored at 3 years after
the date of the MI, or date of loss to follow-up (the earlier of the
date the patient left the practice or the practice stopped
contributing to THIN) if sooner. Percentage yearly changes in
the proportions of people prescribed each medication within
3 months of an MI in primary care were estimated from logistic
regression with generalised estimating equations, adjusting for
age (as a continuous variable), gender and GP. Differences in the
case-fatality and medication trends between men and women
were assessed by the addition of an interaction term for calendar
time and gender. Analyses were carried out using Stata statistical
software (http://www.stata.com).
RESULTS
In all, 10352 patients from 218 general practices had a record of
an MI in THIN between 1991 and 2002, were aged 35 years or
over at the time of diagnosis, and were alive for at least
3 months after the MI date and were thus eligible for inclusion
in the study. There were 6586 men (64%) and 3766 women. The
mean age at diagnosis of the MI was 67.9 years (SD 12.2 years).
Patient characteristics according to calendar year are shown in
supplementary table 1 (available online only). Of those 10352
patients who had survived to 3 months, 1547 (14.9%) died
within 3 years; 887 (8.6%) were censored before the end of the
follow-up and 7918 (76.5%) were censored at 3 years (ie, they
had at least 3 years follow-up).
The ageegender standardised 3-year case-fatality rate among
3-month survivors fell from 83.0 (95% CI 67.9 to 98.1) deaths
per 1000 person-years for patients who had an MI in 1991e2
(followed up to 1994e5) to 61.1 (95% CI 55.8 to 66.4) for
patients who had their MI in 2001e2 (followed up to 2004e5)
(table 1). This corresponds to an average relative decline in the
case-fatality rate of 3.0% per annum (95% CI 1.3 to 4.6,
p<0.001), adjusting for age and gender, equivalent to a decline of
28.1% (95% CI 13.3% to 40.4%) over the 12 years from 1991 to
2002. There was no strong evidence for departure from
a uniform trend in the (log) case-fatality rate over time (p value
for a quadratic term in time 0.2). In gender-speciﬁc analyses,
men showed a consistent and statistically signiﬁcant decline in
case fatality; the average age-adjusted relative decline over the
12 years was 37.0%, 95% CI 20.4 to 50.1, p<0.001. Women
showed a smaller, non-signiﬁcant decline of 14.4%, 95% CI
increase of 11.4 to decline of 34.2, p¼0.2. There was weak
evidence that the time trends differed by gender (the test for
interaction between gender and calendar time was borderline
signiﬁcant; p¼0.06).
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Research reportMedication prescribing data were available for all eligible
patients. Over the same 12-year period, prescribing in primary
care of lipid-lowering drugs in the 3 months following an MI
increased dramatically from 3% of patients in 1991 to 79% in
2002, corresponding to an age and gender-adjusted OR of
prescribing per annum increase in calendar time of 1.79, 95% CI
1.73 to 1.85. Prescribing of beta-blockers increased from 26% to
68% (corresponding OR per annum 1.23, 95% CI 1.20 to 1.26).
Prescribing of ACE inhibitors increased from 11% to 71% (OR
per annum 1.28, 95% CI 1.26 to 1.30) and prescribing of anti-
platelet medication increased from 46% to 86% (OR per annum
1.20, 95% CI 1.17 to 1.23). Prescribing of each of the four
evidenced-based medications increased signiﬁcantly in both men
and women (table 2 and ﬁgure 1). However, female MI patients
consistently received fewer lipid-lowering drugs and
beta-blockers than men. The prescribing of lipid-regulating drugs
increased in men from 4% of patients in 1991 to 83% in 2002,
whereas prescribing increased in women from 1% to 72%. The
prescribing of beta-blockers increased from 33% to 73% in men
compared with an increase from 13% to 60% in women.
Moreover, the prescribing of lipid-regulating drugs increased at a
signiﬁcantly faster rate in men compared with women (p¼0.009
for interaction between gender and calendar time).
DISCUSSION
The longer-term case-fatality rate following an MI (between
3 months and 3 years after the event) fell by 28% between 1991
and 2002. This signiﬁcant improvement in longer-term survival
following an MI is distinct from previously reported
improvements in short-term case fatality. Concurrent large
increases in the prescribing of lipid-lowering drugs,
beta-blockers, ACE inhibitors and anti-platelet drugs in primary
care occurred during the period. Analyses stratiﬁed by gender
suggested a possible inequality in the survival trends, with men
experiencing a greater decline over the study period than
women. Men were also more likely to receive lipid-regulating
drugs and beta-blockers.
The strengths of this study include the large sample size and
nationwide scope of the THIN database, enabling precise esti-
mates of national survival and medication trends. The THIN
database is subject to those limitations inherent in all routinely
collected data (inconsistencies, incompleteness, variation
between GPs). However, death records (the primary outcome)
are reliable in THIN,
16 as are the data on medication prescribing
as all medication prescribed to patients will necessarily be
recorded in the database. Moreover, it has been shown that
THIN is nationally representative in terms of CHD prevalence,
when compared with UK Quality and Outcomes Framework
(QOF) data
17 and the incidence of CHD is comparable to that in
the UK QResearch Primary Care database.
18 Diagnostic criteria
for MI have changed, particularly as a result of the introduction
of troponin. The extent to which the introduction of troponin
has inﬂuenced trends in longer-term survival is unclear, although
correcting for troponin has been shown to have little effect on
estimates of trends in short-term survival following MI.
19
The trends in medication prescribing mirror both reported
increases in the overall numbers of prescriptions for these
medications dispensed (regardless of indication) in England,
1 and
previously reported trends in the prescribing of these medica-
tions in general practice for all forms of CHD in the UK.
20 A
previous UK-based study observed similar gender differences in
medication use after MI.
21 There is a lack of data on contem-
porary trends in longer-term survival following an MI in the UK.
An earlier report found longer-term case fatality among 30-day
survivors to have fallen signiﬁcantly by 34% and 30% in men
and women, respectively, between 1986 and 1995 in Scotland,
Table 1 Mortality rates per 1000 person-years during the 3 years following an MI given survival to 3 months according to calendar year of MI;
standardised to the 2001e2 ageegender distribution in THIN
Calendar
year of MI
All MI patients Men Women
Patients
Person-years
of follow-up Deaths
Standardised
mortality rate, per
1000 person-years
(95% CI) Patients
Person-
years of
follow-up Deaths
Standardised
mortality rate, per
1000 person-years
(95% CI) Patients
Person-
years of
follow-up Deaths
Standardised
mortality rate, per
1000 person-years
(95% CI)
1991e2 604 1440.9 118 83.0 (67.9 to 98.1) 393 945.8 66 73.0 (55.1 to 90.9) 211 495.2 52 103.4 (75.1 to 131.6)
1993e4 895 2139.5 150 73.3 (61.4 to 85.2) 571 1380.4 93 73.9 (58.7 to 89.1) 324 759.2 57 69.9 (51.7 to 88.1)
1995e6 1141 2721.0 175 67.5 (57.4 to 77.6) 716 1741.8 100 60.7 (48.7 to 72.6) 425 979.3 75 77.3 (59.8 to 94.8)
1997e8 1582 3804.2 222 62.9 (54.5 to 71.3) 985 2420.0 121 55.5 (45.5 to 65.4) 597 1384.2 101 76.0 (61.0 to 90.9)
1999e2000 2590 6299.7 370 61.7 (55.4 to 68.0) 1644 4034.2 214 57.0 (49.3 to 64.6) 946 2265.5 156 71.7 (60.4 to 83.0)
2001e2 3540 8338.0 512 61.1 (55.8 to 66.4) 2277 5478.5 286 52.0 (46.0 to 58.0) 1263 2859.5 226 78.6 (68.3 to 88.8)
THIN, the Health Improvement Network database; MI, myocardial infarction.
Table 2 Trend in medication use according to gender: OR for medication use per annum increase in calendar time for men and women
Medication
Men Women
p Value for
genderetime
interaction
% Receiving
medication
in 1991
% Receiving
medication
in 2002
OR per annum
increase in
calendar time
(95% CI) p Value*
% Receiving
medication
in 1991
% Receiving
medication
in 2002
OR per annum
increase in
calendar time
(95% CI) p Value*
Lipid regulating 3.9 83.1 1.83 (1.78 to
1.89)
<0.001 1.28 71.7 1.72 (1.66 to
1.79)
<0.001 0.009
ACE inhibitor 11.6 72.7 1.30 (1.27 to
1.32)
<0.001 10.26 67.1 1.25 (1.22 to
1.28)
<0.001 0.03
Beta-blocker 32.9 73.3 1.22 (1.20 to
1.24)
<0.001 12.82 59.7 1.24 (1.21 to
1.27)
<0.001 0.4
Anti-platelet 47.7 87.1 1.20 (1.18 to
1.22)
<0.001 42.31 83.5 1.20 (1.17 to
1.23)
<0.001 >0.9
*p Value for change in odds of receiving medication per annum increase in calendar time.
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Research reportﬁgures comparable with the more recent trends observed in our
study.
8 By comparison, in Minnesota, USA, 3-year mortality
odds among 28-day survivors fell by 32% in men and by 54% in
women between 1985 and 1995 (the Minnesota Heart Survey).
22
This contrasts with our study in which women experienced
a smaller decline than men, perhaps reﬂecting the earlier time
period and different population. The survey reported concurrent
substantial increases in the in-hospital prescribing of beta-
blockers, ACE inhibitors, high-dose heparin and aspirin for both
men and women, with women marginally less likely to receive
beta-blockers than men, in line with our results. Lipid-lowering
drugs were not considered, again reﬂecting the earlier time
period.
Implications
The results suggest that longer-term case-fatality rates following
an MI, in patients who have survived 3 months, have declined
by one quarter in 12 years. Over the same period substantial
increases in prescribing of relevant evidenced-based medications
have occurred. The rapid rise in prescribing of the four medica-
tion types reﬂects the increasing evidence-base for these medi-
cations over this period. In particular, statin use was negligible
before 1995, a period pre-dating publication of the results of the
major statin trials, whereas a rapid increase in statin prescribing
followed thereafter. Nevertheless, in the last year of this study,
appreciable proportions of MI patients were still not receiving
evidenced-based medication (21% in the case of lipid-lowering
drugs, 30% for beta-blockers and ACE inhibitors) in line with
earlier ﬁndings.
23 Even more recently, appreciable proportions of
post-MI patients in the UK have not been receiving preventive
medications.
20 The question remains as to what factors may
explain the improvement in survival. In terms of short-term case
fatality, the WHO MONICA study found that 18% of the
variation in 28-day case fatality trends in an earlier era from
1980 to 1995 between 31 different populations could be
explained by differences in the trends in the use of beta-blockers,
31% by anti-platelet use and 32% by ACE inhibitors.
24 The
concurrent trends in medication prescribing and survival
observed in our study suggests medication prescribing in
primary care may also have played a role in the decline in longer-
term case fatality. However, medication prescribing alone is
unlikely to be a complete explanation. The decline in longer-
term case death could also reﬂect improved intervention in
hospital during the acute phase (eg, surgical interventions,
rescue coronary angioplasty, thrombolytic agents). In Perth,
Western Australia the 12-year case-fatality rate among patients
who had an MI in 1991e3 and had already survived one year,
was 28% lower than that of their counterparts who had an MI
in 1984e7.
25 This RR reduction did not persist after adjustment
for treatment with thrombolysis, anti-platelets, beta-blockers,
ACE inhibitors and lipid-regulating drugs in hospital and
prescribed on discharge, as well as coronary artery revascular-
isation within 12 months of the incident acute MI, suggesting
that the increased use of these interventions has contributed to
the improvement in survival in this population. In addition,
favourable changes in risk factors, in particular a fall in smoking
prevalence,
1 and nutritional improvement, both in the general
population and in patients with established cardiovascular
disease, are likely to have played a role, as well as improved
emergency response, for example through increased cell phone
use.
26
The differences in the trends in survival according to gender
lend support to the role of factors in addition to/other than
medication prescribing in the trends in survival. Among men,
a steady fall in case fatality occurred alongside a steady increase
in medication prescribing. However, in contrast, among women,
there was no signiﬁcant improvement in case fatality, despite
increases in medication prescribing at almost as fast a rate as for
men, implying the presence of other contributing factors (risk
factors, surgical interventions) that have improved in men but
not in women. In particular, smoking, a key risk factor for MI
incidence and mortality, has declined more steeply in men than
in women,
1 and there are reports of middle-aged women having
Figure 1 Time trend in the proportion
of myocardial infarction (MI) patients
prescribed different relevant
medications in general practice in the
3 months following the MI according to
gender.
What is already known on this topic
< Previous studies have demonstrated declines in incidence of
heart attacks and in 28-day case fatality in recent years in the
UK, which have contributed to the overall decline in coronary
heart disease mortality.
< However, little is known about recent trends in longer-term
survival after a heart attack.
What this study adds
< Three-year survival among patients who have already survived
3 months has improved signiﬁcantly between 1991 and 2005,
although men may have beneﬁted more than women.
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Research reportlower smoking cessation rates than middle-aged men,
27 which
may have contributed to the differential trends in survival. The
suggestion that survival among men may have improved at
a faster rate than among women is of concern as it implies
a widening inequality between men and women, given that
women already had a higher 3-year case-fatality rate than men
at the start of the study in 1991e2. Further research is needed to
validate these ﬁndings.
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